Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Operator Greetings, and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(g) of the Act: None Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its cha ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Dawn Schottlandt - Managing Director-Argot Partners Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Oren Livnat - H.C. Wainwri ...

November 3, 2022 | Nasdaq: COLL Q3FY22 Earnings Report | --- | --- | |----------------------------|-------| | | | | Forward-Looking Statements | | Non-GAAP Financial Measures | --- | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (Sta ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants Greg Fraser - Truist David Amsellem - Piper Sandler Serge Belanger - Needham & Company Tim Lugo - William Blair Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2022 Earnings Call. [Operator Instructions] Please note that this conference is be ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or ...

May 10, 2022 | Nasdaq: COLL Q1FY22 Earnings Report | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - President and CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants David Amsellem - Piper Sandler Lachlan Hanbury-Brown - William Blair Serge Belanger - Needham & Co. Greg Fraser - Truist Securities Brandon Folkes - Cantor Fitzgerald Operator Greetings, and welcome to Collegium Pharmaceutical, Inc. F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...